A Hutchinson Center analysis of participants in the STEP Study—an international HIV-vaccine trial halted in 2007—has confirmed that certain subgroups of male study participants were at higher risk of HIV infection after receiving the experimental vaccine compared to those who received a placebo. The vaccine used in the study did not contain the HIV virus, but it did contain HIV genes that were delivered to cells using a vector that employed a type of cold virus known as adenovirus serotype 5 (Ad5).
Of the 1,836 men examined in this study, 172 became infected with HIV. Within 18 months of enrollment or one year after the last vaccination, men who had neutralizing antibodies to Ad5 or who were uncircumcised, or both, had a twofold to fourfold increased risk of acquiring an HIV infection, according to findings published online in the May 4 edition of the Journal of Infectious Disease.
However, the study also found that the risk level waned after about 18 months to be equal to that of volunteers who received a placebo.
Why this association occurred, what the biological mechanisms were, and why the risk of infection lessened with time are unknown and require more study, according to Dr. Ann Duerr of the Vaccine and Infectious Disease Division, who led the data analysis.
"There seems to be some kind of biologic phenomena that affects infection risk," she said.
The current study indicated that self-reported risk behaviors, such as unprotected sex, did not differ significantly between the vaccine and placebo arms of the STEP trial.
No elevated infection risk in others
The research also confirmed there was no elevated risk of infection in vaccinated men who were circumcised and who were Ad5 seronegative (men who had no neutralizing antibodies to the adenovirus vector used in the vaccine). An earlier interim analysis of the STEP Study data, done after immunizations in the vaccine trial were halted in 2007, also detected this relationship between Ad5 sero-status and vaccine-associated HIV risk. Today, only men who are circumcised and Ad5 seronegative are eligible to receive experimental HIV vaccines that use the adenovirus serotype 5 as a biological delivery mechanism.
Duerr said scientists need a better understanding of what happened biologically to men who became infected, before those who are uncircumcised or seropositive for Ad5 are enrolled in future vaccine trials in which the adenovirus serotype 5 vector is used.
Ad5 is used as a vector because it elicits a strong immune response by CD8 T-cells. These cells are thought to be responsible for controlling HIV infection.
In the current study, researchers analyzed data from male STEP Study participants who enrolled in a trial that provided follow-up for up to four years after they enrolled in the study, or until Dec. 31, 2009, whichever came first.
The STEP Study enrolled 3,000 male and female volunteers in North and South America, the Caribbean and Australia between 2004 and 2007. Injections in the study were halted in September 2007 after researchers detected a lack of effectiveness by the vaccine to prevent HIV acquisition or reduce HIV viral load in infected participants, and a higher-than-expected number of HIV infections in certain subgroups of vaccinees.
Drs. Yunda Huang and Peter Gilbert from the Vaccine and Infectious Disease Division contributed to the research, as did Dr. Larry Corey, Center president and director. Scientists from the San Francisco Department of Public Health, University of Washington, Emory University, Care Resource, Merck Research Laboratories and two Peruvian institutions also coauthored the paper. Merck Research Laboratories and the National Institutes of Health funded the study.